Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

“[This is the] first study to evaluate the replacement of rituximab with odronextamab, which is a [CD20/CD3-targeted] bispecific antibody, in combination with CHOP for patients with previously untreated DLBCL.”

Jean-Marie Michot, MD, a medical doctor in the Department of Hematology and Innovative Drugs at the Institut de Cancérologie Gustave Roussy, discussed the potential clinical relevance of the findings from part 1A of the phase 3 OLYMPIA-3 study (NCT06091865) investigating odronextamab (Ordspono) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

At a median follow-up of 9.2 months (95% CI, 3.7-not evaluable [NE]), among patients who received odronextamab at 80 mg (dose level 1) plus CHOP (n = 9), the mid-induction overall response and complete response (CR) rates were 78% and 33%, respectively; overall, these respective rates were 78% and 44%. The median duration of response (DOR) was not reached (NR; 95% CI, 2.5 months-NE), and the median duration of CR (DOCR) was NR (95% CI, 5.9 months-NE). The median investigator-assessed progression-free survival (PFS) was NR (95% CI, 5.1 months-NE).

At a median follow-up of 7.8 months (95% CI, 3.1-10.3), among those who received odronextamab at 160 mg (dose level 2) in combination with CHOP (n = 13), the mid-induction overall response and CR rates were 100% and 69%, respectively; overall, these rates were both 100%. The median DOR and DOCR were both NR (95% CI, NE-NE). The median investigator-assessed PFS was NR (95% CI, NE-NE).

Disclosures: Michot reported performing consultancy roles for Ideogen, Gilead, Mallinckrodt Pharmaceuticals, GSK, MSD, and Regeneron; and receiving research funding from AbbVie, Agios, Amgen, Argen-x, Astex, AstraZeneca, Beigene, Blueprint, BMS, Boehringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedicine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Seattle Genetics, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor.